Sign in
Taking people in United StatesNo phase

Activity monitor to measure standing time in neurogenic orthostatic hypotension

Tests a wearable monitor for judging treatment of neurogenic orthostatic hypotension.

Key facts

Who runs it
Vanderbilt University Medical Center
Where
Nashville, United StatesSee the site
Trial code
Registry title
Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms
Status
Recruiting
People taking part
29 people, planned
Started
5 Feb 2021
Expected to end
1 Oct 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Accelerometer
  • placebo pill
  • Midodrine or atomoxetine pill
Record updated
2 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with neurogenic orthostatic hypotension, a drop in blood pressure on standing caused by nerve damage. They take midodrine or atomoxetine but still have symptoms.

Age
40 to 80 years
Sex
Men and women
Disease stage
Possible or probable Multiple Systems Atrophy, Pure Autonomic Failure, or Parkinson's disease with neurogenic orthostatic hypotension. This means systolic blood pressure falls by ≥ 30 mmHg within 3 minutes of standing, with faulty nerve reflexes shown on testing.
Earlier treatment
People must already take midodrine or atomoxetine, with some improvement but ongoing symptoms (OHSA score of 1 to 5 on medication). They cannot take more than one medicine for this condition, but pyridostigmine or fludrocortisone are allowed.

Main reasons for not taking part

  • Bedridden, physically disabled or unable to walk
  • OHSA score ≥ 6, or systolic blood pressure drop ≥ 30 mmHg on standing while on regular treatment
  • Pregnancy
  • Illnesses that damage the nerves, such as diabetes mellitus, amyloidosis, monoclonal gammopathies or autoimmune neuropathies
  • Unstable heart disease, heart attack or stroke in the past 6 months, or use of blood thinners (anticoagulants)

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Male and female subjects, age 40-80 years
  • Possible or probable Multiple Systems Atrophy, Pure Autonomic Failure, or Parkinson's disease with neurogenic orthostatic hypotension
  • Neurogenic orthostatic hypotension defined as a ≥ 30 mmHg decrease in systolic blood pressure within 3 minutes of standing associated with impaired autonomic reflexes determined by autonomic testing in the absence of other identifiable causes
  • Patients on treatment for neurogenic orthostatic hypotension with either midodrine or atomoxetine, who have experienced some improvement in their orthostatic symptoms, but still remain symptomatic (Orthostatic hypotension symptom assessment [OHSA] score of 1 to 5 while on medication)
  • Patients who are able to stay with their caregiver during study participation
  • Able and willing to provide informed consent

Who cannot take part

  • Patients taking more than one medication for the treatment of neurogenic orthostatic hypotension (concomitant use of pyridostigmine or fludrocortisone are accepted)
  • Concomitant use of anticoagulants
  • Systemic illnesses known to produce autonomic neuropathy, including but not limited to diabetes mellitus, amyloidosis, monoclonal gammopathies, and autoimmune neuropathies
  • Clinically unstable coronary artery disease (recurrent angina despite medical therapy), or major cardiovascular or neurological event in the past 6 months (myocardial infarction, stroke)
  • Bedridden, physically disabled, or unable to walk
  • Patients with Orthostatic hypotension symptom assessment (OHSA) score ≥ 6, or orthostatic systolic blood pressure drop ≥ 30 mmHg on their regular treatment
  • Pregnancy

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 80 years old?

Where in United States

  • Autonomic Dysfunction Center/ Vanderbilt University Medical CenterNashville, United StatesContact: Emily C Smith, RN MPHTaking people

About the trial

What the trial wants to find out

The objective of this study is to find a more objective and accurate way to assess the efficacy of the treatment for neurogenic orthostatic hypotension. For this purpose, the investigators will use an activity monitor to determine the amount of time patients spend in the upright position (standing and walking; upright time) during 1 week of placebo (a pill with no active ingredients) and 1 week of their regular medication for orthostatic hypotension (midodrine or atomoxetine at their usual doses). Total upright time (i.e. tolerance to standing and walking) will be compared between placebo and active treatment to test the hypothesis that it can be used to assess the efficacy of the treatment for orthostatic hypotension and whether this outcome is superior to the assessment of symptoms using validated questionnaires.

The 2 groups in the trial

  • placeboTreatment being tested

    Placebo pill will be taken for 7 days at the same frequency as their regular treatment with either midodrine or atomoxetine.

    Treatment: Accelerometer and placebo pill

  • Standard treatmentExisting treatment, for comparison

    Either midodrine or atomoxetine at their regular dose.

    Treatment: Accelerometer and Midodrine or atomoxetine pill

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms
Plain-language title
Activity monitor to measure standing time in neurogenic orthostatic hypotensionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT04782830, who can take part
Record updated
2 July 2026